Showing results (61-70 of 78) with videos related to
Sort By:
Pageof 8
The Lancet. Oncology|July 24, 2012
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialAndrea Necchi, Luigi Mariani, Nadia Zaffaroni, et al.Clinical Genitourinary Cancer|May 3, 2014
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinomaPatrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, et al.British Journal of Haematology|May 11, 2012
Phase II study of sorafenib in patients with relapsed or refractory lymphomaAnna Guidetti, Carmelo Carlo-Stella, Silvia L Locatelli, et al.Haematologica|September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trialsDennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.Clinical Genitourinary Cancer|September 7, 2014
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapyAndrea Necchi, Patrizia Giannatempo, Biagio Paolini, et al.Blood|November 16, 2002
BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimensGeorge Z Rassidakis, L Jeffrey Medeiros, Theodoros P Vassilakopoulos, et al.Clinical Genitourinary Cancer|July 22, 2014
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral centerAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.The New England Journal of Medicine|July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is plannedSimonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphomaCorrado Tarella, Roberto Passera, Michele Magni, et al.Lancet (London, England)|March 23, 2015
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H Moskowitz, Auayporn Nademanee, Tamas Masszi, et al.Pageof 8